2417213-72-8
2417213-72-8
Chemical Structure
Teropavimab
Synonym(s): 3BNC117-LS; GS-5423
- CAS No.: 2417213-72-8
- Formula:N/A
- Molecular Weight:(145.889 kDa)
IUPAC Name: (4-bromo-2-chloro-5-fluorophenyl)methanamine hydrochloride
SMILES: [Teropavimab]
Biological Activity: Teropavimab (3BNC117-LS) is a broadly neutralizing antibody targeting the CD4-binding site of the HIV-1 envelope. Teropavimab binds to the CD4-binding site of HIV-1 gp120 to neutralize viruses, including multidrug-resistant HIV-1. Teropavimab can be used in studies related to HIV-1 infection and multidrug-resistant HIV-1 infection[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Teropavimab | 99.70% | Teropavimab (3BNC117-LS) is a broadly neutralizing antibody targeting the CD4-binding site of the HIV-1 envelope. Teropavimab binds to the CD4-binding site of HIV-1 gp120 to neutralize viruses, including multidrug-resistant HIV-1. Teropavimab can be used in studies related to HIV-1 infection and multidrug-resistant HIV-1 infection. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lorenzi JCC, et al. Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates. Journal of virology. 2021 Mar 01;95(5):e01909-20. [Content Brief]
- [2]. Gautam R, et al. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nature medicine. 2018 May;24(5):610-616. [Content Brief]
- [3]. Eron JJ, et al. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV. 2024 Mar;11(3):e146-e155. [Content Brief]
- [4]. Ogbuagu O, et al. Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study. Lancet Microbe. 2026 Mar;7(3):101283. [Content Brief]
- [5]. Spagnuolo V, et al. Teropavimab and zinlirvimab sensitivity in people living with multidrug-resistant HIV-1: data from the PRESTIGIO Registry. Microbiology spectrum. 2025 Oct 07;13(10):e0277724. [Content Brief]
